PDF
version(192 KB PDF)
In vivo assays are not usually performed until or after lead optimization is complete.
This is partly due to the low speed and high cost of conventional animal models
(typically rodents) and the relatively high number of preliminary hits from HTS.
With alternative small-animal models emerging, however, it is now possible to
perform in vivo testing earlier in the process. Thus, researchers have developed
model systems using both invertebrates (the fruit fly and the nematode) and vertebrates
(zebrafish) for drug screening. The small size, high fecundity, and experimental
tractability of these animals enable cost-effective and rapid screening of numerous
compounds.
PDF
version(152 KB PDF)
Drug discovery is now predicated on automated instrumentation, experimentation,
and analysis. For example, the race to map the human genome helped drive the need
for robotic and automated methods in gene sequencing and data handling. R&D
in pharmaceuticals, genomics, proteomics, and molecular diagnostics relies on
automated technologies.
PDF
version(108 KB PDF)
Milwaukee and Madison are just two of the centers of scientific excellence in
Wisconsin, which is rapidly expanding its role in America’s biotech industry.
The Tool Box Lipomic
profiling, profiled(72 KB PDF)
by Amy Adams and Jan Kingsbury
In functional genomics, toxicology, and drug discovery, knowing the full breadth
of lipid metabolism can help.
New
and Noteworthy(88 KB PDF)
IBM activities • Inhibiting autoimmunity • On the critical path •
FDA: Increasing interaction, selectively • Meeting for minds • Profiling
Parkinson’s • SPEEDy siRNA • Delivering a nuclear payload
Looking
for value(56 KB PDF)
by Randall C. Willis
In developing next-generation technology platforms, many biotech companies have
forgotten to generate equity.
Blockbuster
model breaking down(60 KB PDF)
by Ann M. Thayer
Pharma industry reaches new sales peak, despite rising costs and bigger challenges
for drug R&D.
People and Perspectives Moving
from drugs to medicine(48 KB PDF)
by Randall C. Willis
By following a systems approach, researchers and clinicians move toward predicting
and preventing disease.
Diseases and Disorders Cystic
fibrosis: Pipeline of promise(68 KB PDF)
by Linda Richards
After more than a decade of work, drugs help, but a real cure is still a decade
away
Rules and Regulators Arrays
and the FDA(76 KB PDF)
by David Filmore
A new product from Roche Diagnostics is testing the regulatory waters for diagnostic
microarrays.
Clinical Trials Track Assessing
antisense(60 KB PDF)
by David Filmore
An NDA withdrawal signals another setback, but hope remains for next-generation
drugs.
Applications Notebook Mass
identification(156 KB PDF)
Dale H. Patterson and Matthew Willetts
Advancing protein and biomarker discovery with MALDI-TOF/TOF MS technology
